Status:
COMPLETED
AVANDIA With Glyburide In African American And Hispanic Patients With Type 2 Diabetes Not Controlled by Glyburide Alone
Lead Sponsor:
GlaxoSmithKline
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
21+ years
Phase:
PHASE4
Brief Summary
This study was designed to evaluate the safety and efficacy of AVANDIA (rosiglitazone) (8mg once daily) in African American and Hispanic patients with type 2 diabetes mellitus. As microvascular and ma...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- African American or Hispanic.
- Type 2 diabetes mellitus.
- FPG\>=140mg/dL plus HbA1c\>=7.5% whilst receiving SU monotherapy.
- Exclusion criteria:
- Patients who use insulin.
- Clinically significant liver, kidney or heart disease, including high blood pressure.
Exclusion
Key Trial Info
Start Date :
July 28 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 6 2003
Estimated Enrollment :
245 Patients enrolled
Trial Details
Trial ID
NCT00333723
Start Date
July 28 2000
End Date
January 6 2003
Last Update
October 9 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.